Clinical Trials Browser

Phase 1/2 × Myelodysplastic Syndromes × Nivolumab × Clear all

NCT02464657 2021-10-07

Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Phase 1/2 Completed

44 enrolled 12 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute